2011 ADA Posters 1261-2041.indd - Diabetes

esistance and type 2 diabetes. By comprehensive proteomic profi ling of
the human adipocyte secretome we identifi ed DPP4 as a novel adipokine.
This study assessed the association of the adipokine DPP4 to the metabolic
syndrome.
Fully differentiated adipocytes exhibit a substantially higher release of
DPP4, when compared to preadipocytes or macrophages. DPP4 release
from adipocytes is increased after treatment with insulin and TNFα. Direct
addition of DPP4 to adipocytes impairs insulin signaling at the level of
insulin-stimulated Akt phoshorylation. A signifi cantly higher level of DPP4
protein expression was seen in visceral as compared to subcutaneous fat of
obese patients. DPP4 expression in lean subjects was signifi cantly lower in
both depots compared to the obese patients and with no regional difference.
DPP4 serum concentrations signifi cantly correlated with adipocyte size,
serum leptin and various clinical parameters related to the metabolic
syndrome as BMI, fasting insulin and hs-CRP. Using adipose tissue explants
from lean and obese subjects, we observed a 2-fold increase in DPP4 release
in obesity that strongly correlated with adipocyte volume and parameters of
the metabolic syndrome. DPP4 release from adipose tissue was decreased
to the lean level after weight reduction of the obese patients induced by
bariatric surgery. Both circulating DPP4 and DPP4 released from adipose
tissue strongly correlated positively with an increasing risk score for the
metabolic syndrome.
DPP4 is a novel adipokine which may be linked to adipocyte hypertrophy
and adipose tissue infl ammation. As DPP4 release strongly correlates with
adipocyte size, adipose tissue could represent an important source of DPP4
in obesity. We therefore suggest that DPP4 may be critical in linking adipose
tissue and the metabolic syndrome.
& 1856-P
Lipid Accumulation Products Index as a Better Predictor for Insulin
Resistance and Glucose Intolerance Than BMI in Young Obese Women
with Polycystic Ovary Syndrome
JEE-YOUNG OH, HYE JIN LEE, YOUNG SUN HONG, YEON-AH SUNG, Seoul,
Republic of Korea
Elevated waist circumference and elevated triglycerides has been
considered as a surrogate marker of cardiovascular risk. BMI may not to
be the best marker for obesity-related disease. Lipid accumulation product
(LAP) index, an ordinal scale combining waist circumference and triglycerides
concentration, was suggested as a better marker for cardiovascular disease
than BMI.
We examined whether the LAP index is associated with cardiovascular
risk factors and a better predictive marker than BMI in obese women with
polycystic ovary syndrome (PCOS). We recruited 223 obese (BMI ³23kg/m 2 )
women with PCOS and 230 age-, and BMI-matched regular cycling control
women by voluntary participation for the prevalence study. PCOS was
diagnosed by using NICHD, and LAP index was calculated using the formula
[waist circumference(cm)-58] x TG(mmol/L). Glucose intolerance was defi ned
as IFG, IGT or diabetes, and insulin resistance as HOMA value greater than
90 percentile of obese controls.
Mean age and BMI were 24±4 yr and 25.6±2.2 kg/m 2 in PCOS and 24±4 yr
and 25.2±1.8 kg/m 2 in controls. LAP index was signifi cantly higher in women
with PCOS than controls (32.2±21.9 vs. 23.6±15.6, P